DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Asmanex (Mometasone Furoate Inhalation) - Summary

 
 



ASMANEX SUMMARY

ASMANEX« TWISTHALER« 220 mcg
(mometasone furoate inhalation powder)

Mometasone furoate, the active component of the ASMANEX TWISTHALER product, is a corticosteroid.

ASMANEX TWISTHALER inhaler is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older. The ASMANEX TWISTHALER inhaler is also indicated for asthma patients who require oral corticosteroid therapy, where adding ASMANEX TWISTHALER therapy may reduce or eliminate the need for oral corticosteroids.

ASMANEX TWISTHALER is NOT indicated for the relief of acute bronchospasm.


See all Asmanex indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Asmanex (Mometasone Inhalation)

The efficacy and tolerability of inhaled montelukast plus inhaled mometasone compared with mometasone alone in patients with chronic asthma. [2011.06]
BACKGROUND: The efficacy of oral montelukast in chronic asthma is well established. Montelukast is also an effective adjunctive therapy to inhaled corticosteroids (ICS) in asthma uncontrolled on ICS alone. Inhaled montelukast was recently shown to provide significant bronchodilation compared with placebo in patients with chronic asthma. The purpose of this study was to evaluate the efficacy of inhaled montelukast added to inhaled mometasone... CONCLUSION: Inhaled montelukast plus inhaled mometasone was significantly more effective than placebo plus inhaled mometasone in improving FEV(1), symptoms, asthma control, and blood eosinophil count.

Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma. [2010.12]
OBJECTIVE: The combination of inhaled corticosteroid (ICS) and long-acting beta-agonist is recommended for treatment of patients with persistent asthma inadequately controlled on ICS monotherapy. This study was conducted to evaluate the long-term safety of mometasone furoate/formoterol (MF/F) administered through metered-dose inhaler (MDI) in patients with persistent asthma previously on medium- to high-dose ICS... CONCLUSIONS: One-year treatment with the new combination therapies - twice-daily MF/F-MDI 200/10 and 400/10 mug - is safe and well tolerated in patients with persistent asthma.

Efficacy and safety of two dry-powder inhalers for the administration of mometasone furoate in asthma patients. [2010.07]
OBJECTIVE: Mometasone furoate (MF) is a new, potent synthetic inhaled corticosteroid. Worldwide, MF is administered via a dry-powder inhaler that contains multiple doses. As a preparation that would be more cost-effective, single-dose MF capsules were developed in Brazil. The objective of the present study was to evaluate the efficacy and safety of the two inhalers for MF administration in patients with asthma... CONCLUSIONS: The use of the single-dose inhaler developed in Brazil for MF administration is as effective and safe as is that of a standard inhaler in the treatment of patients with asthma.

Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. [2010.01.05]
BACKGROUND: Poor adherence with prescribed asthma medication is a major barrier to positive treatment outcomes. This study was designed to determine the effect of a once-daily administration of mometasone furoate administered via a dry powder inhaler (MF-DPI) on treatment adherence compared with a twice-daily administration... CONCLUSION: Mean adherence rates were greater with a once-daily dosing regimen of MF-DPI than with a twice-daily dosing regimen.This trial was completed prior to the ISMJE requirements for trial registration.

Effect of therapeutic doses of mometasone furoate on cortisol levels in children with mild asthma. [2010.01]
Corticosteroids are the foundation of pharmacologic treatment for children with asthma. However, high-dose inhaled corticosteroid treatment can cause hypothalamic-pituitary-adrenal (HPA) axis suppression...

more studies >>

Clinical Trials Related to Asmanex (Mometasone Inhalation)

Efficacy and Tolerability of Maintenance Treatment With Asmanex Twisthaler Versus Placebo in Mild/Moderate Persistent Asthmatics (Study P04654)(COMPLETED) [Terminated]
This is a randomized, multicenter, placebo-controlled, double-blind, parallel-group study evaluating Asmanex Twisthaler 220 mcg once daily (QD) PM compared with "Asmanex" Placebo QD PM for 12 weeks. Efficacy will be measured for the changes in FEV1 from Baseline to the end of treatment period (Week 12 or end of the study).

Acute Effect of Mometasone Furoate DPI on Beta-adrenergic Airway and Airway Vascular Relaxation in Moderately Severe Asthma [Not yet recruiting]
Glucocorticosteroids inhibit the disposal of organic cations by blocking organic cation transporters expressed by non-neuronal cells, thereby interfering with the inactivation of the organic cations by intracellular enzymes. Beta2-adrenergic agonists are organic cations, and the concentration of inhaled beta2-adrenergic agonists at beta2-adrenergic receptor sites on smooth muscle is likely to be increased by inhaled glucocorticosteroids (ICS) by the ICS' effect on the glucocorticosteroid-sensitive organic cation transporters. The investigators have shown in human airway vascular smooth muscle cells that the glucocorticosteroid action on organic cation uptake occurs within minutes, does not involve gene transcription or protein synthesis, is not mediated through classical steroid receptors, and is cell membrane-linked.

In the present proposal, the investigators wish to use different single doses of mometasone, a clinically effective ICS, administered with or at different times before albuterol inhalation in subjects with moderate persistent asthma who are obstructed at the time of study.

With this approach the investigators will test the hypothesis that a single inhalation of mometasone causes an acute, transient, dose-dependent potentiation of beta2-adrenergic bronchodilation.

If the hypothesis that a single dose of mometasone acutely potentiates beta2-adrenergic bronchodilation is correct, the results would have a significant impact on treatment strategies involving ICSs and beta2-adrenergic agonists in patients with asthma.

Study of Mometasone Furoate/Formoterol Fumarate Inhalation Combination in Healthy Volunteers [Completed]
This study will compare the performance of three combination metered dose inhalation devices and the variability of mometasone and formoterol doses delivered to the lungs in a healthy volunteer population

A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223 AM2) [Recruiting]
The primary objective of this study is to demonstrate the dose-related efficacy, by evaluating morning (AM) lung function at the end of the dosing interval (AM pre-dose percent predicted forced expiratory volume in one second [FEV1]) across 12 weeks of treatment, of three doses (50 mcg, 100 mcg, and 200 mcg) of Mometasone Furoate (MF) Metered Dose Inhaler (MDI) twice a day (BID) compared with Placebo.

Safety and Efficacy of Mometasone Furoate Delivered Via Concept1 or Twisthaler« in Adult and Adolescent Patients With Persistent Asthma [Recruiting]
The purpose of this study is to compare the efficacy, safety and pharmacokinetics of Mometasone furoate delivered via Concept1 or Twisthaler® in adult and adolescent patients with persistent asthma.

more trials >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 3 ratings/reviews, Asmanex has an overall score of 9.33. The effectiveness score is 10 and the side effect score is 8.67. The scores are on ten point scale: 10 - best, 1 - worst.
 

Asmanex review by 35 year old female patient

  Rating
Overall rating:  
Effectiveness:   Highly Effective
Side effects:   No Side Effects
  
Treatment Info
Condition / reason:   asthma
Dosage & duration:   220 mcg (dosage frequency: once a day) for the period of One year+
Other conditions:   None
Other drugs taken:   Albuterol inhaler as needed
  
Reported Results
Benefits:   Preventative control of asthma symptoms.
Side effects:   None that I experienced.
Comments:   This is the best medication I've ever used for my asthma. It's used to prevent the onset of asthma symptoms, and I've found it to be extremely effective. I take it once a day, and it virtually eliminates any asthma symptoms/attacks. I would recommend it to anyone who suffers from asthma.

 

Asmanex review by 38 year old female patient

  Rating
Overall rating:  
Effectiveness:   Highly Effective
Side effects:   Moderate Side Effects
  
Treatment Info
Condition / reason:   Asthma
Dosage & duration:   once a day (dosage frequency: once a day) for the period of 6 months
Other conditions:   none
Other drugs taken:   albuterol when need it
  
Reported Results
Benefits:   It works great, no asthma symptoms.
Side effects:   But I'm loosing a lot of hair, there's mild pain in my lungs and legs on a regular basis and mouth infections.
Comments:   I'm was diagnosed with asthma around six months ago after getting pneumonia that lasted 3 months. I did have allergies before but never any asthma symptoms.

 

Asmanex review by 38 year old female patient

  Rating
Overall rating:  
Effectiveness:   Highly Effective
Side effects:   Moderate Side Effects
  
Treatment Info
Condition / reason:   Asthma
Dosage & duration:   once a day (dosage frequency: once a day) for the period of 6 months
Other conditions:   none
Other drugs taken:   albuterol when need it
  
Reported Results
Benefits:   It works great, no asthma symptoms.
Side effects:   But I'm loosing a lot of hair, there's mild pain in my lungs and legs on a regular basis and mouth infections.
Comments:   I'm was diagnosed with asthma around six months ago after getting pneumonia that lasted 3 months. I did have allergies before but never any asthma symptoms.

See all Asmanex reviews / ratings >>

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014